Glucagon-Like Peptide-1 Receptor Agonists Underused, Particularly in Minorities

Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased during 2015 to 2019 but remains low among patients with type 2 diabetes. Among 1.2 million adults with type 2 diabetes, 7.7% received GLP-1 RAs, with lower rates of use among Asian, Black, Hispanic, and low-income individuals.

Via JAMA Health Forum. Published online December 17, 2021.